NasdaqGS - Nasdaq Real Time Price USD

CG Oncology, Inc. (CGON)

28.80 +2.95 (+11.44%)
As of 11:29 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Arthur Kuan Chairman & CEO 640.97k -- 1991
Mr. Ambaw Bellete M.S. President & COO 1.06M -- 1971
Dr. Vijay Kasturi M.D. Chief Medical Officer 212.24k -- 1968
Ms. Corleen M. Roche CFO & Secretary -- -- 1967
Ms. Amy Steele Vice President of Finance, Accounting & Administration -- -- --
Mr. Swapnil Bhargava Ph.D. Chief Technical Officer -- -- --
Mr. Bing Kung Vice President of Corporate Development -- -- --

CG Oncology, Inc.

400 Spectrum Center Drive
Suite 2040
Irvine, CA 92618
United States
(949) 409-3700 https://cgoncology.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
61

Description

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Corporate Governance

CG Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

KYTX Kyverna Therapeutics, Inc.
15.18
+3.75%
 
ANRO Alto Neuroscience, Inc.
14.23
+0.96%
 
GPCR Structure Therapeutics Inc.
35.87
-0.33%
 
SLRN Acelyrin, Inc.
4.8800
+4.05%
 
AVBP ArriVent BioPharma, Inc.
18.68
+4.18%
 
CABA Cabaletta Bio, Inc.
11.43
+1.51%
 
RYTM Rhythm Pharmaceuticals, Inc.
40.83
+1.57%
 
MGX Metagenomi, Inc.
6.62
+0.99%
 
APGE Apogee Therapeutics, Inc.
54.10
+2.59%
 
JANX Janux Therapeutics, Inc.
48.62
-2.74%